Arena Pharma (ARNA) a short while ago received FDA approval for the weight-loss drug Lorcaserin.
Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss. According to the Centers for Disease Control and Prevention, more than one-third of US adults were obese in 2009-2010. Studies have shown that a weight loss of 5% to 10% of body weight from baseline can result in meaningful improvements in cardiovascular risk factors (e.g., lipids, blood pressure and blood glucose), quality of life and functional capacity, and a significant reduction in the incidence of type 2 diabetes. There are currently limited pharmaceutical treatment options to help patients lose weight.
Lorcaserin becomes the first FDA drug approved to treat obesity in over a decade. The stock was halted prior to the FDA decision to approve the drug. Trading has now resumed on the Arena stock, and the stock just hit a 52 week high of $13.50 a share.
In other news around the Bio Pharma sector, Amarin (AMRN) is poised to receive patent protection for AMR101 which will protect the formulation from generic competition thru 2030.
AMR101 is an investigational ultra-pure omega-3 fatty acid in a capsule, comprising not less than 96% icosapent ethyl (ethyl-EPA) in a capsule. Amarin is developing AMR101 for the potential treatment of patients with very high triglyceride levels and high triglyceride levels, or hypertriglyceridemia. Triglycerides are fats in the blood. Amarin's cardiovascular strategy leverages our extensive knowledge and experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids in cardiovascular disease.
The main patents AMRN has been working on are the '889, '620, '598, and '885. The '889 is a methods patent for treating very high triglycerides, and the '620, '598, and '885 are all iterations of Amarin's composition patents.
Amarin had earlier filed for the key '899 patent for the treatment of high triglycerides that was rejected by the patent office in August 2011, and the stock sold off eventually hitting a low of $5.99 on Dec 15, 2011.
As of this writing, Amarin was trading at 14.53 1.37(10.42%).
DISCLAIMER: This article is intended for informational and entertainment use only and should not be construed as professional investment advice, but rather my opinions as a writer only. Always do you own complete due diligence before buying and selling any stock.